PCI-45261

PCI-45261 is a potent and selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). Developed by Pharmacyclics, it is characterized by its reversible binding mechanism, which distinguishes it from the irreversible (covalent) binding of ibrutinib (PCI-32765). PCI-45261 has been primarily utilized in preclinical research to investigate the biological consequences of transient versus sustained BTK inhibition in B-cell signaling and various B-cell malignancies. By inhibiting BTK, the compound disrupts the B-cell receptor (BCR) signaling pathway, which is essential for the survival and proliferation of malignant B cells. It serves as a critical tool compound for understanding the pharmacology of BTK inhibition without the permanent modification of the target protein.